G
Guangzhou Paizhen Biotechnology
Accelerating gene therapy product development by providing an integrated one-stop solution including plasmid, viral vector, fill-finish and QC analytical services
About Guangzhou Paizhen Biotechnology
PackGene is a rapidly growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in recombinant adeno-associated virus (AAV) vector production. The company provides a comprehensive range of services, from research-grade to clinical-grade plasmid DNA and AAV viral vector production. PackGene's proprietary technology platform utilizes the triple plasmid transfection HEK293 cell process, which is central to delivering high purity, high titer, high infectivity, and high yield AAV vectors, capable of producing up to 1E17 vector genomes per batch.
PackGene serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies engaged in gene therapy research and development. The company operates in the biopharmaceutical market, focusing on gene therapy applications that require high-quality AAV vectors for preclinical and clinical studies.
The business model is service-based, generating revenue through the provision of AAV vector production services. Clients pay for the production of custom AAV vectors tailored to their specific research and clinical needs. Additionally, PackGene offers quality control assays to ensure the identity, purity, content potency, and safety of the AAV vectors produced.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Dec 2023 | $14M | $55M | SDIC Fund Management | ↗ |
| SERIES C✓Equity / VC | Apr 2023 | $0 | — | IFSC | ↗ |
Growth signals
Latest recorded traffic for Guangzhou Paizhen Biotechnology is 15K monthly website visits, up 111.3% over the last three months. Guangzhou Paizhen Biotechnology's team declined 5.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guangzhou Paizhen Biotechnology in the Houston ecosystem
The Guangzhou Paizhen Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- KCKaitai Capital
Series A4 investors entered at this stage
Tengye Venture Capital
Sequoia
Cathay Capital
Decheng Capital
Series B and later3 investors entered at this stage
CMB International Capital- IFIFSC
SDIC Fund Management
Other known investors5 additional known investors
- GFGuangzhou Development District Industrial Fund
- GFGuangzhou Emerging Fund
- GCGuoju Venture Capital
- HRHuacheng Ruisi
- SISanmei Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Paizhen Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Paizhen Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








